This site is for US healthcare professionals to provide online access to current, accurate, scientific information about our products. It is prepared by Janssen Medical Information and is not intended for promotional purposes, nor for medical advice.

  1. Home

IMBRUVICA® (ibrutinib)

IMBRUVICA (ibrutinib)

IMBRUVICA (ibrutinib)

Date Last Updated: 03/03/2021

Janssen Biotech, Inc. and Pharmacyclics, Inc. entered a collaboration and license agreement in December 2011 to co-develop and co-commercialize ibrutinib. For medical information on IMBRUVICA (ibrutinib), please contact Pharmacyclics Medical Information at  or call 1-877-877-3536 or email [email protected].

Please view the full Prescribing Information for IMBRUVICA (ibrutinib) in English.

Scroll to Top